GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » Price-to-Owner-Earnings

Vivos Therapeutics (Vivos Therapeutics) Price-to-Owner-Earnings : (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-05), Vivos Therapeutics's share price is $2.17. Vivos Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Vivos Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


VVOS's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.25
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-05), Vivos Therapeutics's share price is $2.17. Vivos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.93. Therefore, Vivos Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-05), Vivos Therapeutics's share price is $2.17. Vivos Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-11.43. Therefore, Vivos Therapeutics's PE Ratio without NRI for today is At Loss.


Vivos Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Vivos Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics Price-to-Owner-Earnings Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Vivos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivos Therapeutics's Price-to-Owner-Earnings

For the Medical Devices subindustry, Vivos Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos Therapeutics's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Vivos Therapeutics's Price-to-Owner-Earnings falls into.



Vivos Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Vivos Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.17/-5.44
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivos Therapeutics  (NAS:VVOS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Vivos Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Therapeutics (Vivos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Executives
Ronald Kirk Huntsman director, 10 percent owner, officer: Chairman & CEO 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman officer: Chief Financial Officer 6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow director REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson director 2 MUSICK, IRVINE CA 92618
Anja B Krammer director C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh director, 10 percent owner, officer: Chief Medical Officer 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129